Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University Hospital Tuebingen
During the study, the sodium channel blockers phenytoin and lacosamide and the potassium channel blocker kinidinsulfate will be given under standardized conditions to patients with an early onset and pharmaco-resistant genetic epilepsy with and without mutations in the potassium channels KCNT1 and KCNQ2 and the sodium channel gene SCN2A. The primary endpoint will be a significant seizure reduction under trial medication compared to baseline. Secondary endpoints will be the improvement of electroencephalographic characteristics of the respective EEs.
Age
0–1
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
highly active epilepsy (≥ 1 seizure per day)
epilepsy with onset 0-3 months of age
pharmaco-resistant epilepsy (2 or more standard anticonvulsive medications tried before)
recently max. two stable anticonvulsive drugs for minimum 4 days before study start
patients under continuous monitoring control
patients younger than 1 year of age
You may not be if
high grade cardial rhythm disorders
severe liver, renal and electrolyte blood parameter changes
metabolic or lesional origin of epilepsy (metabolic screening results and cranial MRI available)
parallel participation in other studies (must be finished two month before study start)
